combination therapy with glp-1 receptor agonist and sglt2 inhibitor Agonists Inhibitors in Type 2 Diabetes: Pleiotropic Cardiometabolic Effects and Add-on Value of a Combined | Drugs GLP1 Receptor Agonists vs SGLT2-I
Description
Compounding pharmacies operate under federal and state regulations, and the practice is overseen by state pharmacy boards
The increased risk of kidney stones, on the other hand, might be less familiar
In a Phase III trial targeting people with obesity but not diabetes, Novo aimed for 25% weight loss a goal it missed in December
Supporters contend that estimate may overstate the net cost because it does not fully capture potential savings from preventing obesity-related conditions
